NCT06922045

Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

A Phase III Clinical Study on the Efficacy and Safety of STSP-0601 for Injection in Patients With Hemophilia Associated With Inhibitors, With a Multicenter, Open Evaluation Approach

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Jiangsu BioJeTay Biotechnology Co., Ltd. · Industry
• Sex: All
• Age: 12 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitor

Conditions

• Hemophilia

Interventions

Type	Name	Description
DRUG	STSP-0601 for Injection	Evaluation of the Efficacy of Single-Dose and Continuous Administration of STSP-0601 Injection for the Treatment of Bleeding in Patients with Hemophilia A or B with Inhibitors

Timeline

• Start date: 2025-03-26
• Primary completion: 2026-09-01
• Completion: 2026-12-01
• First posted: 2025-04-10
• Last updated: 2025-11-25

Locations

18 sites across 1 country: China